← ANALYST RATINGS · TIPRANKS
Larimar Therapeutics (LRMR): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $16.33, the highest $25.00, the lowest $11.00. The average is +722.8% from the last price of $1.99.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | +0.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | +0.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | +0.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Hold | +0.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Hold | +0.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Sell | +0.8% | Downgrade | 14.10.26on TipRanks 10:05 | — | |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $25.00 | Buy | +1,159.4% | Reiterated | 28.09.26on TipRanks 06:15 | +3.8%next day −0.8% · 5 days −11.0% | ↗ |
| Name not given | — | $12.00 → $13.00+8.3% | Buy | +554.9% | Reiterated | 14.09.26on TipRanks 12:15 | −3.1%next day +3.9% · 5 days −0.6% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $12.00 → $11.00−8.3% | Buy | +454.2% | Reiterated | 05.08.26on TipRanks 08:10 | 0.0%next day +2.6% · 5 days +6.2% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 05.08.26on TipRanks 03:55 | 0.0%next day +2.6% · 5 days +6.2% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $10.00 | Buy | +403.8% | Initiated | 02.07.26on TipRanks 06:10 | +1.7%next day 0.0% · 5 days +29.9% | ↗ |
| Christopher Chen★★★★★★★★★★#5006 · hits 100% · avg +66.9% | Robert W. Baird | $7.00 → $5.00−28.6% | Buy | +151.9% | Reiterated | 30.06.26on TipRanks 07:17 | −5.5%next day +5.4% · 5 days +18.5% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $14.00 | Buy | +605.3% | Reiterated | 30.06.26on TipRanks 06:00 | −5.5%next day +5.4% · 5 days +18.5% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $9.00 | Buy | +353.4% | Reiterated | 29.06.26on TipRanks Jun 30 06:35 | −14.2%next day −5.5% · 5 days +5.7% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $7.00 → $13.00+85.7% | Buy | +554.9% | Reiterated | 24.02.26on TipRanks Mar 12 15:10 | +30.6%next day +60.4% · 5 days +50.3% | |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 06.11.25on TipRanks 09:30 | +8.8%next day −0.4% · 5 days −5.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Larimar Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.75 at a price of $3.19 (+361.7%); now: $16.33 at $1.99 (+722.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 12 | 10 | 6 | 4 |
| Buy | 3 | 3 | 3 | 2 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.34 (from $-0.37 to $-0.30). Last quarter: $-0.30.
Best top-analyst consensus in the sector · Healthcare
About Larimar Therapeutics
- CEO: Carole S. Ben-Maimon
- Employees: 71
- Three Bala Plaza East, Bala Cynwyd, PA, 19004, US
- www.larimartx.com
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Data from the stock’s TipRanks forecast page, read 77 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗